

1 Study Protocol

2 **Device-aided therapies (DATs) in Parkinson's disease (PD). The**
3 **DATs-PD GETM Spanish Registry Protocol Study.**

4 **Santos-García D^{1,2,3,4}, González-Ortega G⁵, Sánchez Alonso P⁶, Planas-Ballvé A⁷, García**
5 **Ramos R⁸, Cabo López I⁹, Blázquez Estrada M¹⁰, Sánchez Ferro A^{11,12}; DATs-PD GETM**
6 **Spanish Registry Group (Appendix 1).**

7 ¹CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. ²Grupo de
8 Investigación en Enfermedad de Parkinson y otros Trastornos del Movimiento, INIBIC (Instituto
9 de Investigación Biomédica de A Coruña), A Coruña, Spain. ³Hospital San Rafael, A Coruña.
10 ⁴Fundación Degen, A Coruña, Spain. ⁵Hospital Universitario de Móstoles, Madrid, Spain.
11 ⁶Hospital Universitario Puerta de Hierro, Madrid, Spain. ⁷Complex Hospitalari Moisès Broggi,
12 Sant Joan Despí, Llobregat, Barcelona, Spain. ⁸Hospital Universitario Clínico San Carlos,
13 Madrid, Spain. ⁹Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.
14 ¹⁰Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain. ¹¹Hospital Universitario 12
15 de Octubre, Madrid, Spain. ¹²Centro de Investigación Biomédica en Red sobre Enfermedades
16 Neurodegenerativas (CIBERNED), Madrid, Spain; Department of Medicine, Universidad
17 Complutense, Madrid, Spain

18

19 **Word count:** abstract 250; text, 2,591 (without references). **Tables:** 1. **Figures:** 1.

20 **Supplementary Material:** None.

21 **Running title:** Device-aided therapies in Parkinson's disease.

It is made available under a [CC-BY 4.0 International license](#) .

Device-aided therapies in Parkinson's disease

22 **Keywords:** Device-aided therapies; Deep Brain stimulation; Infusion; Parkinson's disease;
23 Registry.

24 ***Corresponding author:**

25 Dr. Diego Santos García, Department of Neurology, Hospital Universitario de A Coruña (HUAC),
26 Complejo Hospitalario Universitario de A Coruña (CHUAC), C/ As Xubias 84, 15006, A Coruña,
27 Spain; e-mail: diegosangar@yahoo.es; Tel: + 34 646173341.

28

29 **Abbreviations:** ADL, activities of daily living; CSAI, continuous subcutaneous apomorphine
30 infusion; DATs, device-aided therapies; DBS, deep brain stimulation; fLD/fCD, foslevodopa-
31 foscarnidopa; LCIG, levodopa-carbidopa intestinal gel infusion; LECIG, levodopa-entacapone-
32 carbidopa intestinal gel infusion; LEED, levodopa equivalent daily dose; PD, Parkinson's
33 disease; UPDRS, Unified Parkinson's Disease Rating Scale.

34

35

36

37

38

39

40

41

42

43

44 **ABSTRACT**

45 **Background and objective:** Device-aided therapies (DATs) are treatments indicated for people
46 with Parkinson's disease (PwP) with clinical fluctuations that are not optimally controlled with
47 conventional medication. New DATs have recently emerged such as levodopa-entacapone-
48 carbidopa intestinal gel infusion (LECIG) and subcutaneous infusion of
49 foslevodopa/foscarbidopa (fLD/fCD). It is necessary to know the differences between different
50 DATs.

51 **Patients and Methods:** We present here the protocol study of the DATs-PD GETM Spanish
52 Registry. This is a descriptive, observational, prospective, multicenter, open study that is
53 proposed as a clinical registry with progressive inclusion of PwP treated with a DAT in daily
54 clinical practice conditions in more 40 centers from Spain for 10 years. The principal aim is to
55 know the type of DAT that PwP in our country (Spain) receive. Specific objectives are to
56 compare the clinical characteristics of the patients, the effectiveness, safety and tolerability, to
57 identify predictors of a good response and to analyze the response by groups (gender, disease
58 duration, phenotype, etc.). There is a baseline visit (V1; indication of the therapy), start visit (V2;
59 initiation of the therapy) and follow-up visits at 6 months \pm 3 months (V3_6M) and after this
60 annually \pm 3 months (V3_12M, V3_24M, etc.).

61 **Results:** The registry is on-going. The first patient was included on April 10, 2024. Patient
62 recruitment and follow-up will be conducted until 31/DEC/2033. The estimate is to reach a
63 minimum sample size of at least 3,000 patients.

64 **Conclusion:** The present study will help improve the care of PD patients treated with a DAT.

65

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Device-aided therapies in Parkinson's disease

66 **Authors' Roles:**

67 **Santos-García** D: conception, organization, and execution of the project; funding acquisition;
68 supervision; writing of the first draft of the manuscript; recruitment and/or evaluation of
69 participants; entering data into the database. **González-Ortega** G: preparation and
70 development of the database; registration of participants in the platform; recruitment and/or
71 evaluation of participants; entering data into the database; review and critique. **Sánchez**
72 **Alonso** P: recruitment and/or evaluation of participants; entering data into the database; review
73 and critique. **Planas-Ballvé** A: recruitment and/or evaluation of participants; entering data into
74 the database; review and critique. **García Ramos** R: recruitment and/or evaluation of
75 participants; entering data into the database; review and critique. **Cabo López** I: recruitment
76 and/or evaluation of participants; entering data into the database; review and critique. **Blázquez**
77 **Estrada** M: recruitment and/or evaluation of participants; entering data into the database;
78 review and critique. **Sánchez Ferro** A: collaboration in the coordination of the project as
79 coordinator of GETM; recruitment and/or evaluation of participants; entering data into the
80 database; review and critique.

81

82 **Financial Disclosures for the previous 12 months:**

83 **Santos-García** D. has received honoraria for educational presentations and advice service by
84 Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, Italfarmaco, Teva, Archímedes, Esteve,
85 Stada, Merz, and grants from the "Fundación Professor Novoa Santos" as a result of the
86 "CONVOCATORIA DE AYUDAS PARA LA REALIZACIÓN DE PROYECTOS DE
87 INVESTIGACIÓN PARA GRUPOS EMERGENTES Y ASOCIADOS DEL INIBIC (2023/2024)".

It is made available under a [CC-BY 4.0 International license](#) .

Device-aided therapies in Parkinson's disease

88 **González-Ortega G.** has received honoraria for educational purposes from ABBIE, Zambon,
89 Bial, Esteve and Italfarmaco
90 **Sánchez Alonso P.** has received honoraria for educational presentations and advice service by
91 Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, and Teva.
92 **Planas-Ballvé A:** None.
93 **García Ramos R.** has received honoraria and grants for lecturing, advisory services from
94 Abbvie, Zambón, Bial, Merk, Stada.
95 **Cabo López I.** has received honoraria for educational presentations and advice service by
96 Abbvie, Zambon, Bial, Orion, Italfarmaco and Esteve.
97 **Blázquez Estrada M.** has received honoraria for educational presentations by Dysport, Esteve,
98 Bial, Italfarmaco, Boston Sc. and Stada and for advice service by Esteve, Bial, Suazio.
99 **Sánchez Ferro A.** has received: grants or contracts from ERA-NET Horizon 2020 program
100 JPCOFUND2 (reference number HESOCARE-329-073), MDS (eDiary project), Instituto de
101 Salud Carlos III (reference number P122/01177); consulting fees from Abbvie, Esteve, Orion
102 Pharma, and Prim; and payment or honoraria for lectures, presentations, speakers bureaus,
103 manuscript writing, or educational events from Abbvie, Bayer, Esteve, MDS Society, EAN,
104 Novartis, Monitor, Organon, Roche, SEN, Stada, Teva, and Zambon.
105
106
107
108
109

110 INTRODUCTION

111 Parkinson's disease (PD) is the second most common neurodegenerative disease after
112 Alzheimer's disease. It is characterized by a deficit of dopamine in the striatum and other brain
113 areas, but also of other neurotransmitters such as noradrenaline, acetylcholine or serotonin,
114 which would explain the appearance of motor and non-motor symptoms characteristic of the
115 disease [1]. The diagnosis is made by applying well-defined criteria [2,3] that are based
116 fundamentally on the existence of parkinsonism, the absence of atypical data that suggest an
117 alternative diagnosis (pharmacological, Parkinson-Plus syndrome, etc.), and data in favor that
118 suggest PD itself. Among the latter, a determining aspect is the good response to dopaminergic
119 medication, especially levodopa [4]. Its administration compensates for the deficit of
120 dopaminergic stimulation at the level of the postsynaptic receptors, which causes an
121 improvement in symptoms such as tremor, rigidity or bradykinesia, among others. In fact, the
122 absence of a response would go against the diagnosis of PD.

123 Although the response to dopaminergic medication may be optimal during the first few
124 years, people with PD (PwP) develop motor and non-motor complications (e.g., motor
125 fluctuations, non-motor fluctuations, dyskinesias, etc.) that impact their quality of life and
126 autonomy [5]. Thus, PwP may only perceive improvement at certain times of the day alternating
127 with disabling OFF episodes where the symptoms reemerge and the control with conventional
128 medication is insufficient [6]. Some PwP may benefit from treatment with a second-line therapy
129 that is an alternative and/or complement to conventional medication that is not sufficient [7]. The
130 proper selection of the candidates is key, and there are different tools for their correct
131 identification [8]. These therapies are commonly known as device-aided therapies (DATs) and

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Device-aided therapies in Parkinson's disease

132 although they are more expensive and complex than conventional medication, they have been
133 shown to reduce OFF time, improve non-motor symptoms and the quality of life of PwP [9]. For
134 many years the available DATs in many countries have been the deep brain stimulation (DBS),
135 continuous subcutaneous apomorphine infusion (CSAI) and levodopa-carbidopa intestinal gel
136 infusion (LCIG) [10]. However, new treatments have recently emerged, such as levodopa-
137 entapacone-carbidopa intestinal gel infusion (LECIG) and subcutaneous infusion of
138 foslevodopa-foscarbidopa (fLD/fCD) [11,12]. Particularly relevant is the recent availability of
139 fLD/fCD subcutaneous infusion to the point that many recently published treatment algorithms
140 are outdated and the possibility of considering the subcutaneous route as the first alternative to
141 the enteral route is being discussed, as it is less invasive when considering infusion therapy
142 [13,14].

143 Therefore, a completely new scenario is opening up in the treatment of PwP with a DAT
144 and it is essential to know the frequency of the prescriptions, the characteristics of the treated
145 individuals as well as their long-term evolution in relation to clinical changes and complications.
146 This is the reason why, from the Movement Disorders Study Group (Grupo de Estudio de
147 Trastornos de Movimiento [GETM]) of the Spanish Neurological Society (Sociedad Española de
148 Neurología [SEN]), we have launched a prospective registry of PwP treated with a DAT in our
149 country (Spain). The aim of this article is to describe this registry that we have named DATs-PD
150 GETM Spanish Registry.

151

152 **METHODS/DESIGN**

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Device-aided therapies in Parkinson's disease

153 **Title of the Project:** Device-aided therapies in Parkinson's disease GETM Spanish Registry
154 (DATs-PD GETM Spanish Registry).

155 **Type of study:** Descriptive, observational, prospective, multicenter, open study that is proposed
156 as a clinical registry with progressive inclusion of patients with PwP treated with a DAT in daily
157 clinical practice conditions.

158 **Promoter and principal coordinator of the project:** Diego Santos García, MD, PhD.

159 **Coordinating institutions:** "Fundación Degen", "Grupo de Estudio de Trastornos del
160 Movimiento (GETM)" and "Sociedad Española de Neurología (SEN)".

161 **Participating centers in the project:** More than 40 centers from Spain with neurology teams
162 with experience in the management of PD (**Appendix 1**), including the use of DATs.

163 **Population:** PwP treated with a DAT in Spain from year 2024. The following therapies are
164 included as DATs: DBS; CSAI; LCIG; LECIG; and fLD/fCD subcutaneous infusion. In addition,
165 PwP who are treated with focused ultrasound-guided thermal ablation will also be included.
166 Specifically, the eligibility criteria are: 1) diagnosis of PD according to the MDS criteria; 2) start
167 of treatment with a DAT from January 1, 2024; 3) the patient's desire to participate on a
168 completely voluntary basis; 4) signing of an informed consent.

169 **Justification of the project:** 1) there are many DATs currently used to treat PwP; 2) some of
170 them have been introduced very recently and we have no experience; 3) in this context, we
171 must know about the indication preferences in Spanish centers that treat PwP; 4) we must know
172 the characteristics of the individuals treated and the differences between therapies; 4) we must
173 know the effectiveness of DATs and to compare them; 5) we must know the safety and

It is made available under a [CC-BY 4.0 International license](#) .

Device-aided therapies in Parkinson's disease

174 tolerability of DATs and to compare them; 6) it is necessary to define different response profiles
175 or predictors of better or worse outcome; 7) this is an excellent opportunity to be able to develop
176 a registry at this time that collects a lot of information over the long term; 8) It could be a starting
177 point to which centers from other countries can join and develop a broader registry (e.g.,
178 European, etc.).

179 **Objectives**

180 **Principal objective:** to know the type of DAT that PwP in our country receive, treated by expert
181 neurologists in daily clinical practice conditions.

182 **Specific objectives:** 1) to analyze the sociodemographic and clinical characteristics of PwP
183 treated with a DAT, comparing the different treatments (DBS vs subcutaneous vs enteral
184 treatment); 2) to analyze the effectiveness of different DATs, comparing the different treatments
185 (DBS vs subcutaneous vs enteral treatment); 3) to analyze the safety and tolerability of different
186 DATs, comparing the different treatments; 4) specifically, to analyze the changes experienced
187 by PwP treated with DATs in the perception of their quality of life and autonomy for carrying out
188 daily activities and to compare the different treatments; 5) specifically, to compare the rate of
189 maintenance of the therapy between the different DAT groups; 6) specifically, to compare the
190 dropout rate for each of the therapies and find out the underlying reasons; 7) to find out the
191 reasons for changing from one therapy to another or adding a second DAT to a previous one
192 being received; 8) to analyze the complications in relation to the different DATs and compare
193 them; 9) to compare the differences by gender (male vs. female); 10) others that may be raised
194 based on the data collected (e.g., differences by age, disease duration etc.).

195 **Visits**

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Device-aided therapies in Parkinson's disease

196 The registry includes 3 types of visits: 1) baseline visit (V1), which is when the DAT is decided
197 by the neurologist; 2) start visit (V3), which is when the DAT is initiated by the patient; 3) follow-
198 up visit (V3), with the patient receiving the DAT. The first follow-up visit will be carried out at 6
199 months +/- 3 months (V3_6M) and then at 1 year +/-3 months and subsequently annually +/- 3
200 months: 1 year (V3_12M); 2 years (V3_24M); 3 years (V3_36M); 4 years (V3_48M); 5 years
201 (V3_60M); etc. (**Figure 1**).

202 The period of inclusion of patients in the registry will be a minimum of 5 years, extendable to 10
203 years according to the approved protocol. New PwP will be included over a 10-year period,
204 while each participant's included will be follow-up during this time. The data collection period
205 ranges from January 1, 2024 to December 31, 2033. If a person with PD switches to another
206 DAT or a second DAT is added, the information will be collected. In addition, if a subject drops
207 out of the DAT and does not receive another DAT, data collection will continue within the
208 registry to allow for a comparative arm of untreated patients after a therapeutic failure
209 (something rarely discussed in the literature). Although the registry is prospective, it is planned
210 to include PwP treated in 2024 whose indication for DAT was before this year, as long as the
211 data was properly collected in the medical record. An example is DBS, given that the waiting list
212 from indication to intervention is long in some centers.

213 **Assessments**

214 The following information will be collected at each visit:

- 215 1) Baseline visit (V1): sociodemographic data; data about PD (age onset, disease duration,
216 motor phenotype, etc.); comorbidities; treatments; main reason for therapy indication;
217 levodopa equivalent daily dose (LEDD) [15]; motor symptoms; non-motor symptoms;

218 Unified Parkinson's Disease Rating Scale (UPDRS-III) [16] during the OFF state;
219 UPDRS-III during the ON state; Hoehn & Yahr (H&Y) [17] stage in OFF; H&Y stage in
220 ON; MNCD classification (classification; score; stage) [18]; Parkinson's Disease
221 Questionnaire (PDQ-39) [19]; EUROHIS-QOL 8-item index [20]; Schwab and England
222 Activities of Daily Living Scale (ADLS) [21] during the OFF and during the ON state;
223 serum levels of folate, B vitamins (B1, B6, B12) and homocysteine.

224 2) Start visit (V2): data about the DAT and treatment settings including LEDD.

225 3) Follow-up visit (V3): data about the DAT and treatment settings including LEDD;
226 comorbidities; treatments; LEDD; motor symptoms; non-motor symptoms; UPDRS-III
227 during the ON state; H&Y stage in ON; MNCD classification (classification; score; stage);
228 Parkinson's Disease Questionnaire (PDQ-39); EUROHIS-QOL 8-item index; ADLS
229 during the OFF and during the ON state; serum levels of folate, B vitamins (B1, B6, B12)
230 and homocysteine; complications about the DAT and/or other relevant complications.

231 All information will be collected by expert neurologists in a daily clinical practice setting. A
232 total of 16 and 26 questions collect information on motor symptoms/complications and non-
233 motor symptoms, respectively, which are categorized as absent, mild, moderate, severe, or
234 very severe. The score on the MDS-UPDRS-III scale [22] will be an added option that will be
235 collected in those centers that use it (permission by the MDS was obtained). **Table 1**
236 summarizes the information on the variables that will be collected during the different visits.

237 **Data collection and statistical analysis**

238 Data will be collected using REDCap. This is a secure web application for building and
239 managing online surveys and databases. REDCap has been used to date (27/NOV/2024) in

It is made available under a [CC-BY 4.0 International license](#) .

Device-aided therapies in Parkinson's disease

240 159 countries by more than 3.4 million users. Data collected will be transferred to a statistical
241 package for subsequent analysis. The promoter team of the project will be responsible for study
242 monitoring. The estimate, with the participation of more than 40 centers and a recruitment
243 period of 10 years, is to be able to reach a minimum sample size of 3,000 patients. The
244 pertinent analysis (descriptive, missing data analysis, normality assumptions, univariate, binary
245 logistic regression, multiple linear regression, etc.) will be performed based on the type of
246 objective. In addition, given the complexity of potential analysis including a diversity of variables
247 from different origin and measurement properties, advanced statistical methodology (data
248 mining, machine learning or other artificial intelligence techniques, etc.) could be considered
249 when applicable.

250 **Standard protocol approvals, registrations, and patient consents**

251 The project will be conducted in accordance with the ICH Good Clinical Practice version
252 6 Revision 2 standard, the fundamental ethical principles established in the Declaration of
253 Helsinki and the Oviedo Convention, as well as the Spanish legal requirements for biomedical
254 research (Biomedical Research Law 14/2007). The Project has been approved on 02/APR/2024
255 by the IRB "Comité de Ética de la Investigación Clínica de Galicia from Spain" with code
256 number 2024/109. Written informed consents from all participants in this study will be obtained.

257 **Data availability**

258 The protocol, statistical analysis plan and deidentified participant data will be available
259 on request.

260 **Study timetable**

261 1) Pre-start-up procedures: until April 2024.

262 2) First patient included: 10/APR/2024.

263 3) First analysis to present: 2025 – Q1 (data about PD patients treated in 2024).

264 4) Proposed specific objectives and others: from 2025 onwards.

265 **Funding statement**

266 An amount of 25.000 euros has been granted by the “Fundación Professor Novoa Santos” as a
267 result of the "CONVOCATORIA DE AYUDAS PARA LA REALIZACIÓN DE PROYECTOS DE
268 INVESTIGACIÓN PARA GRUPOS EMERGENTES Y ASOCIADOS DEL INIBIC (2023/2024)".

269 The import will be used for data monitoring and other actions required in the context of the
270 project.

271 **Strengths and limitations of the project**

272 The main strength of the project is the possibility of collecting systematic information on patients
273 treated with DATs over a long follow up period (10 years). Further, there is great interest in the
274 fact that some of these therapies are novel and the management of advanced PD patients is
275 changing because of this and could hence be evaluated. Also, the methodology with
276 prospective follow-up and the collection of well-defined variables (UPDRS, H&Y, PDQ-39,
277 ADLS, etc.) in a clinical practice setting will allow generalizing the findings to other
278 environments. To this end, we also consider in the future increasing the number of centers in
279 Spain, and even the chance of extrapolating the registry to other countries harmonizing the data
280 collected. Other future possibilities are implementing new technologies to monitor the disease
281 and analyze the changes after starting with the DAT and their correlation with the data collected
282 from the registry.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Device-aided therapies in Parkinson's disease

283 On the other hand and as limitations, unlike a study with a clearly defined protocol in which
284 multiple scales are administered [23], this project is a registry, and limitations in the quantity and
285 quality of the data collected are possible. For example, the number and description of
286 complications may be underestimated. At this moment the project is exciting but there is some
287 residual risk that it will not work properly due to the workload of researchers.

288

289 **DISCUSSION**

290 According to the PARADISE study, a non-interventional, cross-sectional, multicenter,
291 national study conducted in the hospital setting and published in 2021, up to 38.2% of people
292 with PD in Spain have advanced PD [24]. The key aspect of identifying advanced PD is to
293 differentiate which PwP could be candidates to receive a DAT. However, only 15.2% of PwP
294 from the advanced PD group from the PARADISE study were receiving some form of therapy
295 for advanced stages of the disease (i.e., DBS, CSAI, LCIG). The most frequent reasons why
296 advanced PwP were not on a DAT were “to be clinically stable” and “option not yet considered”.
297 Similar results were observed in the PROSPECT study [25], in which only 20.9% of PwP (adults
298 with levodopa-responsive PD and inadequately controlled motor symptoms with ≥ 2.5 -hours/day
299 “Off” time, despite trials of available oral/transdermal/sublingual/inhalable medication) initiated a
300 DAT despite the fact that, as expected, DAT vs best medical therapy improved motor
301 symptoms, non-motor symptoms, sleep, quality of life, independence for ADL and caregiver
302 burden. For many years, the options for being treated with a DAT meant choosing between
303 three alternatives: DBS, CSAI, LCIG. However, the scenario is new with the current availability
304 of LECIG and subcutaneous fLD/fCD. In particular, it is of maximum interest to know whether

It is made available under a [CC-BY 4.0 International license](#) .

Device-aided therapies in Parkinson's disease

305 the arrival of fLD/fCD implies a reduction in the indication of other treatments and what are the
306 characteristics of the treated patients as well as their complications in comparison with other
307 DATs, especially enteral therapies [26]. This registry aims to answer this question and many
308 others explained in the objectives. We believe that the information collected in the DATs-PD
309 GETM Spanish Registry will be of great interest in helping to improve the management of
310 people with Parkinson's disease treated with a DAT.

311 In summary, we present here the protocol study of the DATs-PD GETM Spanish
312 Registry, a descriptive, observational, prospective, multicenter, open study that is proposed as a
313 clinical registry with progressive inclusion of PwP treated with a DAT in daily clinical practice
314 conditions in more 40 centers from Spain for 10 years. The present study will help improve the
315 care of PwP treated with a DAT.

316

317

318

319

320

321

322

323

324

325

326

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Device-aided therapies in Parkinson’s disease

327 **Table 1.** Variables collected in the DAT-PD Spanish Registry according to the type of visit.

V1	V2	V3
Sociodemographic	Information about DAT	Information about DAT
PD history	Concomitant treatments	Concomitant treatments
Comorbidities	LEDD	LEDD
Concomitant treatments		PD symptoms
LEDD		Motor symptoms
Main reason for DAT		Non-motor symptoms
PD symptoms		Motor scales
Motor symptoms		UPDRS-III-OFF
Non-motor symptoms		UPDRS-III ON
Motor scales		H&Y-OFF
UPDRS-III-OFF		H&Y-ON
UPDRS-III ON		Quality of life
H&Y-OFF		PDQ-39
H&Y-ON		EUROHIS-QOL8
Quality of life		Functional dependency
PDQ-39		ADLS-OFF
EUROHIS-QOL8		ADLS-ON
Functional dependency		Serum biomarkers
ADLS-OFF		Folate
ADLS-ON		Vitamin B1
Serum biomarkers		Vitamin B6
Folate		Vitamin B12
Vitamin B1		Homocysteine
Vitamin B6		Complications
Vitamin B12		Related with DAT
Homocysteine		Unrelated with DAT

328

329 ADLS, Schwab & England Activities of Daily Living Scale; DAT, device-aided therapy; LEDD, levodopa equivalent
 330 daily dose; PD, Parkinson’s disease; PDQ-39, the 39-item Parkinson’s disease Questionnaire; UPDRS, Unified
 331 Parkinson’s Disease Rating Scale.

332

333

334

335

336

337

338

339

340 **References**

- 341 1. Bloem BR, Okun MS, Klein C. Parkinson's disease. *Lancet* 2021;397:2284-303.
- 342 2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic
343 Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg*
344 *Psychiatry* 1992;55:181-4.
- 345 3. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical
346 diagnostic criteria for Parkinson's disease. *Mov Disord* 2015;30:1591-601.
- 347 4. Santos-García D, de us Fonticoba T, Cores Bartolomé C, et al.; COPPADIS Study Group.
348 Response to levodopa in Parkinson's disease over time. A 4-year follow-up study.
349 *Parkinsonism Relat Disord* 2023;116:105852.
- 350 5. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor
351 fluctuations and dyskinesias in Parkinson disease. *Arch Neurol* 2006;63:1756-60.
- 352 6. Kakimoto A, Kawazoe M, Kurihara K, Mishima T, Tsuboi Y. Impact of non-motor fluctuations
353 on QOL in patients with Parkinson's disease. *Front Neurol* 2023;14:1149615.
- 354 7. Deuschl G, Antonini A, Costa J, et al. European Academy of Neurology/Movement Disorder
355 Society-European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive
356 Therapies. *Mov Disord* 2022;37:1360-74.
- 357 8. Moes HR, Henriksen T, Sławek J, Phokaewvarangkul O, Buskens E, van Laar T. Tools and
358 criteria to select patients with advanced Parkinson's disease for device-aided therapies: a
359 narrative review. *J Neural Transm (Vienna)* 2023;130:1359-77.
- 360 9. Phokaewvarangkul O, Auffret M, Groppa S, Markovic V, Petrovic I, Bhidayasiri R. What was

- 361 first and what is next in selecting device-aided therapy in Parkinson's disease? Balancing
362 evidence and experience. *J Neural Transm (Vienna)* 2024;131:1307-20.
- 363 10. Auffret M, Weiss D, Stocchi F, Vérin M, Jost WH. Access to device-aided therapies in
364 advanced Parkinson's disease: navigating clinician biases, patient preference, and
365 prognostic uncertainty. *J Neural Transm (Vienna)* 2023;130:1411-32.
- 366 11. Santos-García D, López-Manzanares L, Muro I, et al. Effectiveness and safety of levodopa-
367 entacapone-carbidopa infusion in Parkinson disease: A real-world data study. *Eur J Neurol*
368 2024 (epub ahead of print).
- 369 12. Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous
370 foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised,
371 double-blind, active-controlled, phase 3 trial. *Lancet Neurol* 2022;21(12):1099-109.
- 372 13. Antonini A, D'Onofrio V, Guerra A. Current and novel infusion therapies for patients with
373 Parkinson's disease. *J Neural Transm (Vienna)* 2023;130:1349-58.
- 374 14. Aubignat M, Tir M. Continuous Subcutaneous Foslevodopa-Foscarbidopa in Parkinson's
375 Disease: A Mini-Review of Current Scope and Future Outlook. *Mov Disord Clin Pract*
376 2024;11:1188-94.
- 377 15. Nyholm D, Jost WH. An updated calculator for determining levodopa-equivalent dose.
378 *Neurol Res Pract* 2021;3:58.
- 379 16. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's
380 Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. *Recent*
381 *developments in Parkinson's disease, Vol 2*. Florham Park, NJ: Macmillan Health Care

382 Information;1987.p-153-64.

383 17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology*

384 1967;17:427-42.

385 18. Santos García D, Álvarez Sauco M, Calopa M, et al. MNCD: A New Tool for Classifying

386 Parkinson's Disease in Daily Clinical Practice. *Diagnostics (Basel)* 2021;12:55.

387 19. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease

388 Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary

389 index score. *Age Ageing* 1997;26:353-7.

390 20. Da Rocha NS, Power MJ, Bushnell DM, Fleck MP. The EUROHIS-QOL 8-item index:

391 comparative psychometric properties to its parent WHOQOL-BREF. *Value Health*

392 2012;15:449-57.

393 21. Schwab RS, England AC. In *Third Symposium on Parkinson's disease*. E. And S.

394 Livingstone: Edinburgh 1969;152-7.

395 22. Goetz CG, Tilley BC, Shaftman SR, et al.; Movement Disorder Society UPDRS Revision

396 Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's

397 Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov*

398 *Disord* 2008;23:2129-70.

399 23. Santos-García D, Mir P, Cubo E, Vela L, et al.; COPPADIS Study Group. COPPADIS-2015

400 (COhort of Patients with PARKinson's Disease in Spain, 2015), a global--clinical evaluations,

401 serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-

402 interventional, long-term study on Parkinson's disease progression. *BMC Neurol*

It is made available under a [CC-BY 4.0 International license](#) .

Device-aided therapies in Parkinson's disease

403 2016;16:26.

404 24. Martínez-Castrillo JC, Martínez-Martín P, Burgos Á, et al. Prevalence of Advanced
405 Parkinson's Disease in Patients Treated in the Hospitals of the Spanish National Healthcare
406 System: The PARADISE Study. Brain Sci 2021;11(12):1557.

407 25. Dean MN, Standaert DG. Levodopa infusion therapies for Parkinson disease. Curr Opin
408 Neurol 2024;37:409-413.

409 26. de Fabregues O, Falconer D, Heshmat S, et al. Long-Term Evolution of Advanced
410 Parkinson's Disease Burden: Subgroup Analysis from the 24 Month International
411 PROSPECT Observational Study [abstract]. Mov Disord 2024;39(suppl 1).

412

413

414

415

416

417

418

419

420

421

422

423

424

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Device-aided therapies in Parkinson's disease

425 **Legend of Figures**

426 **Figure 1.** All patients treated with a DAT from 2024 to 31/DEC/2033 in more than 40
427 participating centers from Spain are included, all of them evaluated by neurologists who are
428 experts in PD. Each color refers to a different patient. There is a baseline visit (V1; indication of
429 the therapy), start visit (V2; initiation of the therapy) and follow-up visits at 6 months (V3_6M)
430 and after this annually (V3_12M, V3_24M, etc.). The window for V2 and V3 is \pm 3 months.

431

432 **Acknowledgements**

433 We would like to thank all patients who collaborated in this study. Many thanks also to
434 Fundación Española de Ayuda a la Investigación en Enfermedades Neurodegenerativas y/o de
435 Origen Genético (<https://fundaciondegen.org/>), Grupo de Estudio de Trastornos del Movimiento
436 (GETM), Sociedad Española de Neurología (SEN) and Fundación Profesor Novoa Santos.

437

438

439

440

441

442

443

444

445

446

447 **Appendix 1.**

448 **DATs-PD GETM Spanish Registry STUDY GROUP**

449 Adarmes Gómez AD, Alonso Modino D, Álvarez Saucó M, Aneiros Díaz A, Ávila Rivera A,
450 Baviera-Muñoz R, Belmonte S, Blázquez Estrada M, Caballero Sánchez L, Caballol Pons N,
451 Cabo López I, Campins Romeu M, Campolongo A, Cantarero Duque S, Carrillo García F,
452 Casanova Mollá J, Casas Peña E, Castaño García B, Castellano Guerrero AM, Castrillo Sanz
453 A, Cerdán Santacruz DM, Clavero Ibarra P, Cores Bartolomé C, Cots Foraster A, Cubo Delgado
454 E, Delgado Ballesteros T, Erdocia Goñi A, Escalante Arroyo S, Escamilla Sevilla F, Espinosa
455 Rosso R , Fanjul Arbos S, Feliz Feliz C, Fernández Pajarín G, Fernández Revuelta A,
456 Fernández Rodríguez B, Fernández Valle T, Freire Álvarez E, Gamo González E, García
457 Fernández C, García Herruzo A, García Ramos García R, García Ruíz Espiga P, Garrote
458 Espina L, Gil Villar MP, Gómez Esteban JC, Gómez López de San Román C, Gómez
459 Mayordomo V, Gómez Rapela C, González MV, González Ardura J, González Hernández A,
460 González-Ortega G, Guerra Hiraldo JD, Gutiérrez García J, Hernández Vara J, Jesús Maestre
461 S, Kulisevsky Bojarski J, Legarda Ramírez I, López Ariztegui N, López Dominguez D, López
462 Manzanares L, López Veloso AC, López Valdés E, Lorenzo Barreto P, Lorenzo Brito JM,
463 Lozano D, Macías García D, Madrid Navarro CJ, Martí Andrés G, Martí Martínez S, Martín
464 García R, Martínez Castrillo JC, Martínez-Torres I, Mata Álvarez Santullano M, Mauri Fabrega
465 L, Méndez Guerrero A, Mendoza Rodríguez A, Mir Rivera P, Mondragón Rezola E, Monterde
466 Ortega A, Morales Casado MI, Morata-Martínez C, Muñoz Delgado L, Muñoz Ruíz T, Muro I,
467 Novo Ponte S, Ojeda Lepe E, Olivares Romero J, Pagonabarraga J, Pareés Moreno I, Pascual
468 Sedano B, Paz González JM, Peral Quirós A, Pérez Calvo C, Pérez Rangel D, Perona

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Device-aided therapies in Parkinson's disease

469 Moratalla A, Planas-Ballvé A, Prendes Fernández P, Quibus Requena L, Rábano Suárez P,
470 Rashid López R, Rebollo Lavado B, Rojas Pérez E, Ribacoba Díaz C, Romero Fábrega JC,
471 Ruiz López M, Ruíz Martínez J, Samaniego Vinueza LB, San Eufrasio Martínez M, Sánchez
472 Alonso P, Sánchez Ferro A, Sánchez Rodríguez A, Sancho Saldana A, Santos-García D,
473 Sastre Bataller I, Sesar Ignacio A, Solano Vila B, Solleiro Vidal A, Suárez San Martín E, Tabar
474 Comellas G, Tijero Merino B, Triguero Cueva L, Valero García MF, Valldeoriola Serra F, Vela L,
475 Vinagre Aragón A, Vivas Villacampa L, Vives Pastor B, Yáñez Baña R.

476

First Name	Last Name	Centre
Diego	Santos García	Complejo Hospitalario Universitario de A Coruña
Jose Manuel	Paz González	Complejo Hospitalario Universitario de A Coruña
Carlos	Cores Bartolomé	Complejo Hospitalario Universitario de A Coruña
Lucia Belen	Samaniego Vinueza	Complejo Hospitalario Universitario de A Coruña
Ángela	Solleiro Vidal***	Complejo Hospitalario Universitario de A Coruña
María	Álvarez Sauco	Hospital General Universitario de Elche
Eric	Freire Álvarez	Hospital General Universitario de Elche
Juan Carlos	Martínez Castrillo	Hospital Universitario Ramón y Cajal
Isabel	Pareés Moreno	Hospital Universitario Ramón y Cajal
Samira	Fanjul Arbos	Hospital Universitario Ramón y Cajal
Ana Belén	Perona Moratalla	Complejo Hospitalario Universitario de Albacete
Inés	Legarda Ramírez	Hospital Universitario Son Espases
Bàrbara	Vives Pastor	Hospital Universitario Son Espases
María Fuensanta	Valero García	Hospital Universitario Son Espases
Esther	Cubo Delgado	Hospital Universitario de Burgos
Nuria	López Ariztegui	Hospital Universitario de Toledo
Maria Isabel	Morales Casado	Hospital Universitario de Toledo
Guillermo	Tabar Comellas	Hospital Universitario de Toledo
Déborah	Alonso Modino	Hospital Universitario de la Candelaria
Jesús Norelis	Lorenzo Brito	Hospital Universitario de la Candelaria
Esther	Rojas Pérez	Hospital Universitario de la Candelaria
Iria	Cabo López	Complejo Hospitalario Universitario de Pontevedra

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Device-aided therapies in Parkinson's disease

Jorge	Hernández Vara	Hospital Universitario Vall d'Hebron
Maria Victoria	González	Hospital Universitario Vall d'Hebron
Sara	Belmonte**	Hospital Universitario Vall d'Hebron
Juan Carlos	Romero Fábrega	Hospital Universitario Virgen de las Nieves
Francisco	Escamilla Sevilla	Hospital Universitario Virgen de las Nieves
Lucía	Triguero Cueva	Hospital Universitario Virgen de las Nieves
Carlos Javier	Madrid Navarro	Hospital Universitario Virgen de las Nieves
Rosa	Yáñez Baña	Complejo Hospitalario Universitario de Ourense
Asunción	Ávila Rivera	Complex Hospitalari Moisès Broggi
Núria	Caballol Pons	Complex Hospitalari Moisès Broggi
Ana	Planas-Ballvé	Complex Hospitalari Moisès Broggi
Alejandro	Peral Quirós	Complex Hospitalari Moisès Broggi
Dolors	Lozano	Complex Hospitalari Moisès Broggi
Álvaro	Sánchez Ferro	Hospital 12 de Octubre
Pablo	Rábano Suárez	Hospital 12 de Octubre
Antonio	Méndez Guerrero	Hospital 12 de Octubre
Daniel	Pérez Rangel	Hospital 12 de Octubre
Frances	Valldeoriola Serra	Hospital Clínic
Rocío	García Ramos	Hospital Clínic Universitario San Carlos
Ana	Fernández Revuelta	Hospital Clínic Universitario San Carlos
Eva	López Valdés	Hospital Clínic Universitario San Carlos
Carmen	Ribacoba Díaz	Hospital Clínic Universitario San Carlos
Irene	Martínez-Torres	Hospital Universitario la Fe
Carlos	Morata-Martínez	Hospital Universitario la Fe
Raquel	Baviera-Muñoz	Hospital Universitario la Fe
Marina	Campins Romeu	Hospital Universitario la Fe
Isabel	Sastre Bataller	Hospital Universitario la Fe
Pilar	Sánchez Alonso	Hospital Puerta de Hierro
Sabela	Novo Ponte	Hospital Puerta de Hierro
Elisa	Gamo González	Hospital Puerta de Hierro
Raquel	Martín García	Hospital Puerta de Hierro
Pablo	Mir Rivera	Hospital Universitario Virgen del Rocío
Laura	Muñoz Delgado	Hospital Universitario Virgen del Rocío
Astrid Daniela	Adarmes Gómez	Hospital Universitario Virgen del Rocío
Elena	Ojeda Lepe	Hospital Universitario Virgen del Rocío
Silvia	Jesús Maestre	Hospital Universitario Virgen del Rocío

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Device-aided therapies in Parkinson's disease

Daniel	Macías García	Hospital Universitario Virgen del Rocío
Fátima	Carrillo García	Hospital Universitario Virgen del Rocío
Ana María	Castellano Guerrero***	Hospital Universitario Virgen del Rocío
Manuela	San Eufrasio Martínez***	Hospital Universitario Virgen del Rocío
Cristina	Pérez Calvo***	Hospital Universitario Virgen del Rocío
Andrés	García Herruzo	Hospital Universitario Virgen del Rocío
Cristina	Gómez Rapela****	Hospital Universitario Virgen del Rocío
Lorena	Garrote Espina****	Hospital Universitario Virgen del Rocío
Marta	Blázquez Estrada	Hospital Universitario Central de Asturias
Esther	Suárez San Martín	Hospital Universitario Central de Asturias
Ciara	García Fernández	Hospital Universitario Central de Asturias
Patricia	Prendes Fernández****	Hospital Universitario Central de Asturias
Pedro	García Ruíz Espiga	Hospital Fundación Jiménez Díaz
Cici	Feliz Feliz	Hospital Fundación Jiménez Díaz
Raúl	Espinosa Rosso	Hospital Universitario de Jerez
Lara	Mauri Fabrega	Hospital Universitario de Jerez
Jaime	Kulisevsky Bojarski	Hospital Sant Pau de Barcelona
Berta	Pascual Sedano	Hospital Sant Pau de Barcelona
Javier	Pagonabarraga	Hospital Sant Pau de Barcelona
Antonia	Campolongo**	Hospital Sant Pau de Barcelona
Marina	Mata Álvarez-Santullano	Hospital Universitario Infanta Sofía
Juan Carlos	Gómez Esteban	Hospital de Cruces
Tamara	Fernández Valle	Hospital de Cruces
Marta	Ruiz López	Hospital de Cruces
Beatriz	Tijero Merino	Hospital de Cruces
Lydia	López Manzanares	Hospital Universitario La Princesa
Inés	Muro	Hospital Universitario La Princesa
Elena	Casas Peña	Hospital Universitario La Princesa
Pablo	Lorenzo Barreto	Hospital Universitario La Princesa
Maria Pilar	Gil Villar	Hospital Universitari Arnau de Vilanova
Agustín	Sancho Saldana	Hospital Universitari Arnau de Vilanova
Laura	Quibus Requena	Hospital Universitari Arnau de Vilanova
Jesús	Olivares Romero	Hospital Universitario de Torrecárdenas
Belén	Rebollo Lavado	Hospital Universitario de Torrecárdenas
Lucía	Triguero Cueva*	Hospital Universitario de Torrecárdenas
Víctor	Gómez Mayordomo	Hospitales Vithas

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Device-aided therapies in Parkinson's disease

Berta	Solano Vila	Hospital Josep Trueta de Girona y Hospital Santa Caterina de Salt
Anna	Cots Foraster	Hospital Josep Trueta de Girona y Hospital Santa Caterina de Salt
Daniel	López Dominguez	Hospital Josep Trueta de Girona y Hospital Santa Caterina de Salt
Lilian	Vivas Villacampa	Hospital Josep Trueta de Girona y Hospital Santa Caterina de Salt
Jessica	González Ardura	Hospital de Cabueñes
Belén	Castaño García	Hospital de Cabueñes
Antonio	Sánchez Rodríguez	Hospital de Cabueñes
Sonia	Escalante Arroyo	Hospital Virgen de la Cinta
Tania	Delgado Ballester	Parc Taulí
Débora María	Cerdán Santacruz	Hospital General de Segovia
Amelia	Mendoza Rodríguez	Hospital General de Segovia
Ana	Castrillo Sanz	Hospital General de Segovia
Lorena	Caballero Sánchez	Hospital General de Segovia
Claudia	Gómez López de San Román	Hospital General de Segovia
Gustavo	Fernández Pajarín	Complejo Hospitalario Universitario de Santiago de Compostela
Ángel	Sesar Ignacio	Complejo Hospitalario Universitario de Santiago de Compostela
Jordi	Casanova Mollá	Hospital Universitario Sant Joan de Reus
Ángela	Monterde Ortega	Hospital Universitario Joan XXIII
Susana	Cantarero Duque	Hospital Universitario de Móstoles
Guillermo	González-Ortega	Hospital Universitario de Móstoles
Beatriz	Fernández Rodríguez	Hospital Regional Universitario de Málaga
Teresa	Muñoz Ruíz	Hospital Regional Universitario de Málaga
Gloria	Martí Andrés	Hospital Universitario de Navarra, Pamplona, Navarra
Pedro	Clavero Ibarra	Hospital Universitario de Navarra, Pamplona, Navarra
Amaia	Erdocia Goñi	Hospital Universitario de Navarra, Pamplona, Navarra
Ana Carolina	López Veloso	Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria
Ayoze Nautzet	González Hernández	Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria
Juan Diego	Guerra Hiraldo	Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria
Raúl	Rashid López	Hospital Puerta del Mar, Cádiz
Raúl	Espinosa Rosso	Hospital Puerta del Mar, Cádiz
Silvia	Martí Martínez	Hospital General Universitario Alicante
Ángel	Aneiros Díaz	Complejo Hospitalario Universitario de Ferrol
Lydia	Vela	Hospital Fundación de Alcorcón
Javier	Ruíz Martínez	Hospital Universitario Donostia
Elisabet	Mondragón Rezola	Hospital Universitario Donostia
Ana	Vinagre Aragón	Hospital Universitario Donostia

It is made available under a [CC-BY 4.0 International license](#) .

Device-aided therapies in Parkinson's disease

Javier	Gutiérrez García	Complejo Hospitalario Granada
--------	------------------	-------------------------------

477

478 The researchers are listed by center in chronological order according to the date they confirmed their participation in
479 the project.

480 * This investigator works at 2 different centers.


481 All investigators are neurologists except those ones with the symbol: ** SN (specialized nurse); ***graduate in Biology

482 (she will be responsible for remote data monitoring); ****neuropsychologist; ***** , study coordinator.



All PD patients treated with a DAT in more than 40 centers participating

10 years of recruitment period and follow-up



Figure